TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Atopic Dermatitis
Brief Summary: A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclosporine A | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ciclosporine A; Assigned to Arm(s): 2
B: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo qw
C: Arm Label: Group1; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group2; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group3; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group4; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group5; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331), Other: Placebo | Intervention Type: DRUG; Name: nemolizumab (CIM331); Assigned to Arm(s): Group1, Group2, Group3, Group4, Group5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group5
D: Arm Label: Apremilast 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Placebo + Apremilast 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo | Arm Label: Placebo + Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 40 mg, Placebo + Apremilast 40 mg | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg, Placebo + Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Apremilast 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Placebo + Apremilast 30 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Multi-phase, Multi-dose, Prospective, Double-blind, Placebo-controlled, Maintenance Study of Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate) in Hyperkalemia.
Brief Summary: It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was established during the open-label acute phase versus no difference between each ZS dose (highest to lowest) versus placebo control (null hypothesis).


Options:
A: Arm Label: Patiromer; Type: ACTIVE_COMPARATOR; Interventions: Drug: Patiromer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sodium Polystyrene Sulfonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium polystyrene sulfonate | Arm Label: Lactose with carob gum; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose with carob gum | Intervention Type: DRUG; Name: Sodium polystyrene sulfonate; Assigned to Arm(s): Sodium Polystyrene Sulfonate | Intervention Type: DRUG; Name: Lactose with carob gum; Assigned to Arm(s): Lactose with carob gum
C: Arm Label: Sodium zirconium cyclosilicate 10 g three times daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Placebo once daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sodium zirconium cyclosilicate 5 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 10 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 15 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Intervention Type: DRUG; Name: Sodium zirconium cyclosilicate; Assigned to Arm(s): Sodium zirconium cyclosilicate 10 g once daily, Sodium zirconium cyclosilicate 10 g three times daily, Sodium zirconium cyclosilicate 15 g once daily, Sodium zirconium cyclosilicate 5 g once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo once daily
D: Arm Label: Group 1 - Dosing Without Food; Type: EXPERIMENTAL; Interventions: Drug: patiromer | Arm Label: Group 2 - Dosing With Food; Type: ACTIVE_COMPARATOR; Interventions: Drug: patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Group 1 - Dosing Without Food, Group 2 - Dosing With Food

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Walking Training With Partial Body Weight Support on Static and Dynamic Surfaces in Individuals With Hemiparesis Due to Stroke
Brief Summary: The purpose of this study is evaluate the effects of walking training with partial body weight support on static (floor) and dynamic (treadmill) surfaces in individuals with hemiparesis due to stroke. For this purpose, two training protocols will be employed in three experimental groups: G1 will do the walking training with partial body weight support on static surfaces and G2 will do the walking training with partial body weight support on dynamic surfaces


Options:
A: Arm Label: Static surface; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Static surface | Arm Label: dynamic surface; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Dynamic surface | Intervention Type: PROCEDURE; Name: Static surface; Assigned to Arm(s): Static surface | Intervention Type: PROCEDURE; Name: Dynamic surface; Assigned to Arm(s): dynamic surface
B: Arm Label: Early Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early locomotor training program | Arm Label: Late Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Late locomotor training program | Arm Label: Early Home Exercise Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Exercise Program | Intervention Type: BEHAVIORAL; Name: Early locomotor training program; Assigned to Arm(s): Early Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Late locomotor training program; Assigned to Arm(s): Late Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Home Exercise Program; Assigned to Arm(s): Early Home Exercise Program
C: Arm Label: Treadmill walking; Type: EXPERIMENTAL; Interventions: Behavioral: treadmill walking with partial weight support | Arm Label: Overground walking; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: assisted overground walking | Intervention Type: BEHAVIORAL; Name: treadmill walking with partial weight support; Assigned to Arm(s): Treadmill walking | Intervention Type: BEHAVIORAL; Name: assisted overground walking; Assigned to Arm(s): Overground walking
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: intensified gait trainer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: intensified gait trainer | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intensified gait trainer; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study.
Brief Summary: The corneal collagen cross linking is currently used in the treatment of keratoconus but this procedure has also a sterilizing non-specific effect on bacteria and fungus. So the corneal cross linking in association with the antibiotic treatment could result in a reduction of the duration of epithelial complete healing of the cornea.


Options:
A: Arm Label: antibiotic treatment alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: antibiotic treatment | Arm Label: Crosslinking + Antibiotic; Type: EXPERIMENTAL; Interventions: Device: Crosslinking, Drug: antibiotic treatment | Intervention Type: DEVICE; Name: Crosslinking; Assigned to Arm(s): Crosslinking + Antibiotic | Intervention Type: DRUG; Name: antibiotic treatment; Assigned to Arm(s): Crosslinking + Antibiotic, antibiotic treatment alone
B: Arm Label: Collagen crosslinking group; Type: EXPERIMENTAL; Interventions: Procedure: collagen crosslinking group, Drug: Topical anti-fungal therapy | Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Topical anti-fungal therapy | Intervention Type: PROCEDURE; Name: collagen crosslinking group; Assigned to Arm(s): Collagen crosslinking group | Intervention Type: DRUG; Name: Topical anti-fungal therapy; Assigned to Arm(s): Collagen crosslinking group, standard medical therapy
C: Arm Label: Kpro with crosslinked graft-support; Type: EXPERIMENTAL; Interventions: Procedure: Crosslinking with riboflavin of the corneal graft-support | Arm Label: KPro with normal graft-support; Type: ACTIVE_COMPARATOR; Interventions: Procedure: De-epithelisation of the corneal graft support with instillation of riboflavin | Intervention Type: PROCEDURE; Name: Crosslinking with riboflavin of the corneal graft-support; Assigned to Arm(s): Kpro with crosslinked graft-support | Intervention Type: PROCEDURE; Name: De-epithelisation of the corneal graft support with instillation of riboflavin; Assigned to Arm(s): KPro with normal graft-support
D: Arm Label: epithelium off CXL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transepithelial versus epithelium-off CXL, Drug: Isotonic riboflavin | Arm Label: Ricrolin TE CXL; Type: EXPERIMENTAL; Interventions: Procedure: Transepithelial versus epithelium-off CXL, Drug: Ricrolin TE | Intervention Type: PROCEDURE; Name: Transepithelial versus epithelium-off CXL; Assigned to Arm(s): Ricrolin TE CXL, epithelium off CXL | Intervention Type: DRUG; Name: Ricrolin TE; Assigned to Arm(s): Ricrolin TE CXL | Intervention Type: DRUG; Name: Isotonic riboflavin; Assigned to Arm(s): epithelium off CXL

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Brief Summary: Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical management will be uniform for all randomized treatment groups and will be centrally directed.


Options:
A: Arm Label: Carotid Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid endarterectomy (CEA) | Arm Label: Carotid Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Stenting (CAS) | Arm Label: Intensive Medical Management - no CEA; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CEA | Arm Label: Intensive Medical Management - no CAS; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CAS | Intervention Type: PROCEDURE; Name: Carotid endarterectomy (CEA); Assigned to Arm(s): Carotid Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Stenting (CAS); Assigned to Arm(s): Carotid Stenting (CAS) | Intervention Type: OTHER; Name: Intensive Medical Management - no CEA; Assigned to Arm(s): Intensive Medical Management - no CEA | Intervention Type: OTHER; Name: Intensive Medical Management - no CAS; Assigned to Arm(s): Intensive Medical Management - no CAS
B: Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: reserpine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Brief Summary: Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical management will be uniform for all randomized treatment groups and will be centrally directed.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid artery stenting with filter (interventional) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid artery endarterectomy (surgical) | Intervention Type: DEVICE; Name: Carotid artery stenting with filter (interventional); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Carotid artery endarterectomy (surgical); Assigned to Arm(s): 2
B: Arm Label: MICHI NPS+f; Type: EXPERIMENTAL; Interventions: Device: MICHI NPS+f | Intervention Type: DEVICE; Name: MICHI NPS+f; Assigned to Arm(s): MICHI NPS+f
C: Intervention Type: DEVICE; Name: Cordis Nitinol Stent; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: PRECISE tapered stent; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ANGIOGUARD XP Emboli Capture Guidewire (ECGW); Assigned to Arm(s): N/A
D: Arm Label: Carotid Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid endarterectomy (CEA) | Arm Label: Carotid Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Stenting (CAS) | Arm Label: Intensive Medical Management - no CEA; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CEA | Arm Label: Intensive Medical Management - no CAS; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CAS | Intervention Type: PROCEDURE; Name: Carotid endarterectomy (CEA); Assigned to Arm(s): Carotid Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Stenting (CAS); Assigned to Arm(s): Carotid Stenting (CAS) | Intervention Type: OTHER; Name: Intensive Medical Management - no CEA; Assigned to Arm(s): Intensive Medical Management - no CEA | Intervention Type: OTHER; Name: Intensive Medical Management - no CAS; Assigned to Arm(s): Intensive Medical Management - no CAS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Trial on Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia
Brief Summary: To compare the efficacy and cost-effectiveness between purified CD34+ cells and peripheral blood mononuclear cells in treatment of critical limb ischemia


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
B: Arm Label: 4times injection; Type: EXPERIMENTAL; Interventions: Biological: 4times injection | Arm Label: one injection; Type: EXPERIMENTAL; Interventions: Biological: stem cell transplantation | Intervention Type: BIOLOGICAL; Name: 4times injection; Assigned to Arm(s): 4times injection | Intervention Type: BIOLOGICAL; Name: stem cell transplantation; Assigned to Arm(s): one injection
C: Arm Label: autologous purified CD34+ cell; Type: EXPERIMENTAL; Interventions: Other: autologous purified CD34+ cells | Arm Label: autologous PB-MNC; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous peripheral blood mononuclear cells | Intervention Type: OTHER; Name: autologous purified CD34+ cells; Assigned to Arm(s): autologous purified CD34+ cell | Intervention Type: OTHER; Name: autologous peripheral blood mononuclear cells; Assigned to Arm(s): autologous PB-MNC
D: Arm Label: Allogeneic Mesenchymal Stromal Cell; Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Stromal Cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Stromal Cell; Assigned to Arm(s): Allogeneic Mesenchymal Stromal Cell | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes.
Brief Summary: The purpose of this study is to assess efficacy and safety of a single low-dose Primaquine added to standard artemether/lumefantrine treatment for the clearance of Plasmodium falciparum gametocytes among patients with uncomplicated malaria aged 1 year and above regardless of their G6PD status.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: primaquine (PQ) plus SP+AS | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP) plus artesunate (AS); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: primaquine (PQ) plus SP+AS; Assigned to Arm(s): 2
D: Arm Label: artemether-lumefantrine+placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (For artemether-lumefantrine arm) | Arm Label: artemether-lumefantrine+primaquine; Type: EXPERIMENTAL; Interventions: Drug: Primaquine (For artemether-lumefantrine+primaquine arm) | Intervention Type: DRUG; Name: Primaquine (For artemether-lumefantrine+primaquine arm); Assigned to Arm(s): artemether-lumefantrine+primaquine | Intervention Type: DRUG; Name: Placebo (For artemether-lumefantrine arm); Assigned to Arm(s): artemether-lumefantrine+placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Association Between Low Cortisol Level and Whiplash Syndrome and the Effect of a Single Hydrocortisone Injection on Neck Symptoms Among Motor Vehicle Accident Victims: a Randomized Placebo Controlled Double Blinded Study
Brief Summary: The investigators hypothesis is that low (or low relatively to the situation) cortisol levels might be a causative factor of whiplash injury or post traumatic stress disorder following road accidents. In this study the investigators enroll patients who sustained a road accident. From all patients a blood sample will be withdrawn to measure cortisol concentrations. Than, the patients will be divided into 2 groups: the study group will receive a single injection of intravenous Hydrocortisone 100 milligram (a synthetic steroid used routinely for many years). The control group will receive a same volume of normal saline which would be used as a placebo treatment. The investigators assume that patients with low cortisol levels would tend to have a higher incidence of whiplash injuries and / or post traumatic stress disorders, and that a single bolus of hydrocortisone may prevent these untoward sequelas of trauma.


Options:
A: Arm Label: Hydrocortisone injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline 0.9% | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone injection | Intervention Type: DRUG; Name: normal saline 0.9%; Assigned to Arm(s): normal saline
B: Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Oxepa; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding., Dietary Supplement: oxepa | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control group | Intervention Type: DIETARY_SUPPLEMENT; Name: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.; Assigned to Arm(s): Oxepa | Intervention Type: DIETARY_SUPPLEMENT; Name: oxepa; Assigned to Arm(s): Oxepa | Intervention Type: DIETARY_SUPPLEMENT; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sertraline; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline

Answer: A